Baxter International (BAX) Aktienübersicht
Baxter International Inc. bietet über seine Tochtergesellschaften ein Portfolio von Gesundheitsprodukten in den Vereinigten Staaten an. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 2/6 |
| Dividenden | 0/6 |
BAX Community Fair Values
Create NarrativeSee what 35 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Baxter International Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$22.65 |
| 52-Wochen-Hoch | US$31.22 |
| 52-Wochen-Tief | US$15.73 |
| Beta | 0.64 |
| 1 Monat Veränderung | 21.25% |
| 3 Monate Veränderung | 35.79% |
| 1 Jahr Veränderung | -26.96% |
| 3 Jahre Veränderung | -50.34% |
| 5 Jahre Veränderung | -72.15% |
| Veränderung seit IPO | 1,630.87% |
Aktuelle Nachrichten und Updates
Analyseartikel • Jun 21
Baxter International (BAX) Stock Could Be 7.7% Undervalued After MediThinQ Distribution Deal
Synovis Micro Companies Alliance, a subsidiary of Baxter International (BAX), has signed an exclusive multi-year deal with MediThinQ to distribute the SHIYA 3D surgical visualization platform globally, expanding Baxter’s footprint in digital surgical technology. See our latest analysis for Baxter International. The MediThinQ agreement arrives after a volatile stretch for Baxter International, with a 19.75% 90 day share price return contrasting with a 33.11% decline in 1 year total shareholder...
Narrativ-Update • Jun 14
BAX: Back Half Execution And CFO Uncertainty Will Drive A Bearish Outlook
The analyst price target for Baxter International has shifted modestly lower to $17.00 from $18.00, as analysts factor in expectations for a year weighted more toward the second half, leadership uncertainty surrounding the CFO search, and relatively more appealing valuations in other medical technology stocks. Analyst Commentary Recent research on Baxter International has turned more cautious, with several bearish analysts revisiting their ratings and price targets in light of company specific and sector wide factors.
Narrativ-Update • May 31
BAX: Back Half Execution Will Shape Margin Recovery And Rerating Potential
Analysts have trimmed their overall price expectations for Baxter International, with the updated fair value estimate easing slightly to about $21.54 from $21.63. Recent target cuts, including Citi's move to $17 and other adjustments across the Street, reflect concerns around a back-half weighted year, the ongoing CFO search, and revised assumptions for profit margins and future P/E multiples.Narrativ-Update • May 14
BAX: Mixed Price Signals And Margin Pressures Will Shape A Cautious Fair Outlook
Analysts now place Baxter International's fair value at $18.00, up from $17.00, reflecting updated assumptions for discount rate, growth, margins, and expected future P/E after a mix of recent price target cuts and a more recent $2 increase from the Street. Analyst Commentary Recent research has been mixed, with several bearish analysts trimming price targets over the past few months even as one bank lifted its target by US$2.Recent updates
Analyseartikel • Jun 21
Baxter International (BAX) Stock Could Be 7.7% Undervalued After MediThinQ Distribution Deal
Synovis Micro Companies Alliance, a subsidiary of Baxter International (BAX), has signed an exclusive multi-year deal with MediThinQ to distribute the SHIYA 3D surgical visualization platform globally, expanding Baxter’s footprint in digital surgical technology. See our latest analysis for Baxter International. The MediThinQ agreement arrives after a volatile stretch for Baxter International, with a 19.75% 90 day share price return contrasting with a 33.11% decline in 1 year total shareholder...Narrativ-Update • Jun 14
BAX: Back Half Execution And CFO Uncertainty Will Drive A Bearish Outlook
The analyst price target for Baxter International has shifted modestly lower to $17.00 from $18.00, as analysts factor in expectations for a year weighted more toward the second half, leadership uncertainty surrounding the CFO search, and relatively more appealing valuations in other medical technology stocks. Analyst Commentary Recent research on Baxter International has turned more cautious, with several bearish analysts revisiting their ratings and price targets in light of company specific and sector wide factors.Narrativ-Update • May 31
BAX: Back Half Execution Will Shape Margin Recovery And Rerating Potential
Analysts have trimmed their overall price expectations for Baxter International, with the updated fair value estimate easing slightly to about $21.54 from $21.63. Recent target cuts, including Citi's move to $17 and other adjustments across the Street, reflect concerns around a back-half weighted year, the ongoing CFO search, and revised assumptions for profit margins and future P/E multiples.Narrativ-Update • May 14
BAX: Mixed Price Signals And Margin Pressures Will Shape A Cautious Fair Outlook
Analysts now place Baxter International's fair value at $18.00, up from $17.00, reflecting updated assumptions for discount rate, growth, margins, and expected future P/E after a mix of recent price target cuts and a more recent $2 increase from the Street. Analyst Commentary Recent research has been mixed, with several bearish analysts trimming price targets over the past few months even as one bank lifted its target by US$2.Seeking Alpha • May 08
Baxter International Still Has A Path To Upside
Summary In recent years, stocks like Baxter International have underperformed: most low-growth, high-debt, struggling names have been bad investments at basically any price. Concerns are real, and early missteps under new CEO Andrew Hider haven't helped. But valuation is attractive not just on an absolute basis but also relative to the outlook, and Q1 results seemed helpful to the bull case. Time and patience should change investors perspectives toward BAX, at which point the stock should be back above $20. Read the full article on Seeking Alpha
Narrativ-Update • Apr 29
BAX: 2026 Margin Execution And Cost Clarity Will Drive Repricing Potential
Narrative Update The analyst price target for Baxter International has been trimmed by $0.09 as analysts factor in recent sector wide target cuts and concerns about margin pressures and limited near term visibility following the company's 2026 outlook. Analyst Commentary Recent research coverage on Baxter International has centered on margin headwinds, higher non operating items, and an outlook that many see as underwhelming, particularly into 2026.Narrativ-Update • Apr 14
BAX: Margin Pressures And Execution Risks Will Shape A More Balanced Outlook
Analyst fair value for Baxter International has been reset from $15.00 to $17.00 as analysts factor in updated revenue growth, margin assumptions, and sector level price target cuts across recent research notes. Analyst Commentary Recent research has centered on resetting expectations for Baxter International, with bearish analysts trimming price targets and highlighting execution and earnings risk tied to the latest guidance.Narrativ-Update • Mar 31
BAX: 2026 Execution And Margin Visibility Will Determine Potential Upside Repricing
Analysts have edged Baxter International's fair value estimate higher to about $33.38 from $32.59, even as several firms recently reduced their price targets to a range of $17 to $30 after underwhelming 2026 guidance and margin pressures. Analyst Commentary Recent Street research has centered on Baxter's 2026 outlook, with several firms trimming price targets after guidance and margin commentary fell short of earlier expectations.Narrativ-Update • Mar 16
BAX: Future Margin Stability And 2026 Outlook Could Unlock Upside Potential
Analysts have trimmed Baxter International's fair value estimate from $43.95 to $32.59, citing lower price targets in the $17 to $30 range and updated assumptions for slower revenue growth, slimmer margins, a higher discount rate, and a richer future P/E multiple. Analyst Commentary Recent Street research on Baxter reflects a cautious tone overall, but there are still pockets of constructive commentary that matter if you are weighing the new fair value estimate against external views.Narrativ-Update • Mar 02
BAX: Q4 Reset And 2026 Outlook Will Test Margin Recovery Hopes
Analysts have trimmed their average 12 month price target for Baxter International by several dollars into the high teens, pointing to weaker than expected 2026 margin guidance and limited near term visibility as key drivers of the reset. Analyst Commentary Recent research shows a clear reset in expectations for Baxter International, with most firms trimming price targets and highlighting weaker 2026 guidance as a key catalyst.Narrativ-Update • Feb 16
BAX: Q4 Results And 2026 Outlook Will Clarify Fairly Balanced Risks
The updated analyst price target for Baxter International has decreased by about $1.50, as analysts cite limited visibility around the company’s 2026 outlook while still accounting for modest adjustments to growth, margins, and future P/E expectations. Analyst Commentary Recent research updates show a mix of caution and selective optimism around Baxter International, with several firms revising price targets and reassessing how much uncertainty is already reflected in the shares.Narrativ-Update • Feb 02
BAX: Q4 Results And 2026 Outlook Will Resolve Discounted Uncertainty
Analysts have made only minor tweaks to their modeled discount rate, revenue growth, profit margin, and future P/E for Baxter International, resulting in a relatively stable fair value estimate around $23.13. In contrast, Street price targets have shifted modestly, with one firm trimming its view to $30 and another nudging its target to $23 as they factor in current uncertainty and the potential clarity from upcoming results and the 2026 outlook.Narrativ-Update • Jan 19
BAX: Q4 And 2026 Outlook Will Reduce Uncertainty And Support Margin Recovery
Narrative Update: Baxter International Analyst Price Target Shift Analysts have modestly reduced their blended price target on Baxter International, with updated modeling pointing to a fair value trim of about US$0.67 per share to US$23.13, as they factor in lower future P/E assumptions and recent guidance cuts, partly balanced by slightly firmer revenue growth expectations. Analyst Commentary Recent research shows a clear split between bullish analysts, who see current uncertainty as already reflected in the share price, and bearish analysts, who focus on execution risk and softer guidance.Narrativ-Update • Jan 05
BAX: Earnings Headwinds And Margin Pressure Will Drive A Lower Share Repricing
Analysts have reduced their fair value estimate for Baxter International from about US$19.00 to about US$15.00 per share, reflecting lower price targets of US$22.00 (previously US$25.00) and more modest expectations for growth and margins following recent results and guidance cuts. Analyst Commentary Bearish analysts are resetting expectations on Baxter International after recent quarterly results and guidance cuts, pointing to weaker execution and softer growth than previously anticipated.Narrativ-Update • Dec 15
BAX: Margin Recovery Will Follow New Leadership And Cost Discipline Over Time
Analysts have trimmed their fair value estimate for Baxter International slightly, from approximately $24.07 to $23.80 per share, reflecting reduced price targets to around $22 in light of softer sales, margin pressure, and lowered guidance that signal ongoing near term earnings headwinds. Analyst Commentary Analyst sentiment around Baxter International remains mixed, with recent earnings results and guidance prompting a more cautious stance on the stock despite its reduced valuation.Narrativ-Update • Dec 01
BAX: Margin Recovery Will Follow New CEO’s Drive for Operational Efficiency
Analysts have lowered their price target for Baxter International from $25 to $22. They cite weaker-than-expected sales, margin pressures, continued business headwinds, and reduced forward guidance as key factors behind the adjustment.Narrativ-Update • Nov 17
BAX: Margin Headwinds Will Ease With New CEO and Business Resilience
Analysts have lowered their price target for Baxter International from $25 to $22 per share. They cite disappointing recent sales performance and ongoing margin pressures that are expected to persist into 2026.Narrativ-Update • Nov 03
BAX: Near-Term Headwinds Will Resolve As Margins Stabilize Into 2026
Analysts have reduced their price target for Baxter International from approximately $28 to $24.07 per share. They cite persistent revenue headwinds, lower margins, and management's more cautious outlook for 2025 and beyond.Narrativ-Update • Oct 20
Hospital Normalization And Demographic Trends Will Support Connected Healthcare
Baxter International’s analyst price target has been lowered from approximately $29.47 to $28.00. Analysts cite slower-than-expected progress in margin expansion and revenue growth following disappointing earnings and reduced guidance.Narrativ-Update • Oct 05
Hospital Normalization And Demographic Trends Will Support Connected Healthcare
Analysts have lowered their price targets for Baxter International to $25 from previous levels above $36, citing concerns about slower than expected margin expansion, delayed sales growth recovery, and business challenges highlighted in recent guidance cuts. Analyst Commentary Recent analyst reports have provided a mixed outlook for Baxter International, highlighting both challenges and potential positives as the company navigates through a period of transition and recovery.Narrativ-Update • Sep 05
Hospital Normalization And Demographic Trends Will Support Connected Healthcare
Baxter International's consensus price target was slightly reduced to $29.00, as disappointing Q2 results, lowered full-year guidance, and a slower-than-expected path to sales and margin improvement undermined near-term growth confidence. Analyst Commentary Disappointing Q2 performance and reduced full-year guidance undermined near-term confidence in Baxter's growth trajectory.Seeking Alpha • Apr 21
Baxter: Messy, Yet Appealing, If New Management Can Deliver
Summary Baxter's sale of its kidney business, Vantive, was executed at a low price, raising concerns about its ability to effectively deleverage its balance sheet. Despite the sale, Baxter's net debt remains high, and adjusted earnings are under pressure, with a significant reduction in the dividend indicating anticipated earnings challenges. The company's leadership change and modest organic growth provide some hope, but the highly adjusted earnings and mixed track record create an opaque investment outlook. Shares appear reasonably priced, but the situation remains fluid and uncertain, making it difficult to have strong conviction about improved shareholder outcomes. Read the full article on Seeking AlphaSeeking Alpha • Jan 31
Baxter International: An Uncompelling Investment With High Debt
Summary Recent capital allocation decisions have been questionable. The stock doesn't really seem to fit compellingly within a portfolio constructed along the lines of any popular investment approaches. Baxter International seems pretty uncompelling as an investment opportunity, and investors should look elsewhere. Read the full article on Seeking AlphaSeeking Alpha • Aug 07
Baxter- Reiterating Our Buy Rating After A Promising Q2
Summary BAX's Novum IQ Large Volume Pumps are playing a key role in driving topline progress, whilst the HST division too looks set to benefit from a few tailwinds. BAX's revamped operating model is paying off with strong operating leverage expected this year (14% bottomline growth on 3% topline growth). The current yield is already quite compelling at over 3%, but the sale or spin-off of the Kidney Care Division by Q1-25 could lead to a long overdue dividend hike. Baxter offers good mean-reversion prospects as it looks beaten down versus other medical device stocks, whilst the recent price action has been encouraging as well. Read the full article on Seeking AlphaSeeking Alpha • Jul 16
Baxter: Why Investors Should Take Advantage Of The Low Valuation
Summary Baxter has been a poor performer over the last year. The stock now trades with an extremely low valuation relative to the stock's historical performance. Recently, the company raised guidance, which points to double-digit earnings growth. Analysts seem to believe this growth is sustainable. Baxter has plans to sell its least profitable business to focus on higher margin segments. Read the full article on Seeking AlphaAktionärsrenditen
| BAX | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 5.1% | 1.4% | 1.6% |
| 1Y | -27.0% | -21.6% | 21.1% |
Rendite im Vergleich zur Industrie: BAX unter dem Niveau der Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -21.6% erzielte.
Rendite vs. Markt: BAX hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 21.1 erzielte.
Preisvolatilität
| BAX volatility | |
|---|---|
| BAX Average Weekly Movement | 5.3% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: BAX hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: BAXDie wöchentliche Volatilität (5%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1931 | 37,500 | Andrew Hider | www.baxter.com |
Baxter International Inc. bietet über seine Tochtergesellschaften ein Portfolio von Gesundheitsprodukten in den Vereinigten Staaten an. Das Unternehmen ist in drei Segmenten tätig: Medizinische Produkte & Therapien, Gesundheitssysteme & Technologien und Pharmazeutika. Es bietet sterile intravenöse (IV) Lösungen, Infusionssysteme und -geräte, parenterale Ernährungstherapien, Inhalationsanästhetika, generische injizierbare Arzneimittel, chirurgische Hämostatika und Versiegelungsprodukte, fortschrittliche chirurgische Ausrüstung, intelligente Bettsysteme, Patientenüberwachung und Diagnosetechnologien und Geräte für die Atemwegsgesundheit sowie fortschrittliche Ausrüstung für den chirurgischen Bereich, einschließlich Technologien zur Integration in den Operationssaal, Präzisionspositionierungsgeräte und anderes Zubehör.
Baxter International Inc.'s Grundlagenzusammenfassung
| BAX grundlegende Statistiken | |
|---|---|
| Marktanteil | US$11.20b |
| Gewinn(TTM) | -US$981.00m |
| Umsatz(TTM) | US$11.32b |
1.0x
Kurs-Umsatz-Verhältnis-11.9x
Kurs-Gewinn-Verhältnis Ist BAX zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| BAX Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$11.32b |
| Kosten der Einnahmen | US$7.40b |
| Bruttogewinn | US$3.92b |
| Sonstige Ausgaben | US$4.90b |
| Gewinn | -US$981.00m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -1.90 |
| Bruttomarge | 34.65% |
| Nettogewinnspanne | -8.67% |
| Schulden/Eigenkapital-Verhältnis | 157.3% |
Wie hat sich BAX auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
0.2%
Aktuelle Dividendenrendite-19%
AusschüttungsquoteUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/02 21:31 |
| Aktienkurs zum Tagesende | 2026/07/02 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Baxter International Inc. wird von 33 Analysten beobachtet. 13 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Matthew Taylor | Barclays |
| Matthew Miksic | Barclays |